tetano
Editor, Senior Moderator
Cureus
. 2021 Sep 1;13(9):e17644.
doi: 10.7759/cureus.17644. eCollection 2021 Sep.
Development of Arterial Thrombosis in a Patient on Therapeutic Anticoagulation for COVID-19
Essam K Nagori[SUP] 1 [/SUP], Rory Smith[SUP] 1 [/SUP], Fernando Sorto[SUP] 2 [/SUP], Mufadda Hasan[SUP] 2 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) virus has been known to manifest various non-pulmonary complications in the affected patient, including both venous and less frequently, arterial thrombosis. Ongoing research is necessary to determine who might benefit from therapeutic anticoagulation as well as potentially develop an algorithm to predict thromboembolic events in this patient population. We present a case of a 65-year-old man with a past medical history of hypertension, diabetes type 2, and a previous cerebrovascular accident who was admitted with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). On admission to the hospital, the patient was initiated on therapeutic anticoagulation. Subsequently, he developed left lower limb ischemia. Imaging discovered arterial thrombosis in the bilateral deep femoral and left popliteal arteries. Consequently, the patient required catheter directed thrombolysis for partial reperfusion. Unfortunately, the patient succumbed to the complications of COVID-19. This case is notable in that it highlights the arterial thrombophilia associated with COVID-19 despite early intervention with therapeutic anticoagulation.
Keywords: anticoagulation; arterial; covid-19; hypercoagulable; sars-cov-2; thrombosis.
. 2021 Sep 1;13(9):e17644.
doi: 10.7759/cureus.17644. eCollection 2021 Sep.
Development of Arterial Thrombosis in a Patient on Therapeutic Anticoagulation for COVID-19
Essam K Nagori[SUP] 1 [/SUP], Rory Smith[SUP] 1 [/SUP], Fernando Sorto[SUP] 2 [/SUP], Mufadda Hasan[SUP] 2 [/SUP]
Affiliations
- PMID: 34646692
- PMCID: PMC8485964
- DOI: 10.7759/cureus.17644
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) virus has been known to manifest various non-pulmonary complications in the affected patient, including both venous and less frequently, arterial thrombosis. Ongoing research is necessary to determine who might benefit from therapeutic anticoagulation as well as potentially develop an algorithm to predict thromboembolic events in this patient population. We present a case of a 65-year-old man with a past medical history of hypertension, diabetes type 2, and a previous cerebrovascular accident who was admitted with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19). On admission to the hospital, the patient was initiated on therapeutic anticoagulation. Subsequently, he developed left lower limb ischemia. Imaging discovered arterial thrombosis in the bilateral deep femoral and left popliteal arteries. Consequently, the patient required catheter directed thrombolysis for partial reperfusion. Unfortunately, the patient succumbed to the complications of COVID-19. This case is notable in that it highlights the arterial thrombophilia associated with COVID-19 despite early intervention with therapeutic anticoagulation.
Keywords: anticoagulation; arterial; covid-19; hypercoagulable; sars-cov-2; thrombosis.